

Review

## Molecular determinants and regulation of *Leishmania* virulence

Kwang-Poo Chang\*<sup>1</sup> and Bradford S McGwire<sup>2</sup>

Address: <sup>1</sup>Department of Microbiology/Immunology, University of Health Sciences/Chicago Medical School, North Chicago, IL, USA and <sup>2</sup>Department of Pathology, The Feinberg School of Medicine, Northwestern University and Section of Infectious Diseases, College of Medicine, University of Illinois-Chicago, Chicago, IL, USA

E-mail: Kwang-Poo Chang\* - changk@finchcms.edu; Bradford S McGwire - bmcgwire@uic.edu

\*Corresponding author

Published: 20 May 2002

Received: 21 March 2002

*Kinetoplastid Biology and Disease* 2002, 1:1

Accepted: 20 May 2002

This article is available from: <http://www.kinetoplastids.com/content/1/1/1>

© 2002 Chang and McGwire; licensee BioMed Central Ltd. Verbatim copying and redistribution of this article are permitted in any medium for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

A *Leishmania* model to explain microbial virulence in chronic infectious diseases is proposed. All these diseases progress from infection to symptomatic phase to host death or recovery. The outcome of each phase is depicted to result from the interactions of a distinct group of parasite molecules with a specific host immune compartment. The first group consists of invasive/evasive determinants, which are largely parasite cell surface and secreted molecules. Their activities help parasites establish infection by overcoming host immunologic and non-immunologic barriers. These determinants do not cause disease *per se*, but are indispensable for infection necessary for the development of a disease-state. The second group of parasite molecules consists of "pathoantigenic" determinants – unique parasite epitopes present often within otherwise highly conserved cytoplasmic molecules. Immune response against these determinants is thought to result in immunopathology manifested as clinical signs or symptoms, namely the virulent phenotype. The third group of parasite molecules is hypothetically perceived as vaccine determinants. Their interactions with the host immune system lead to the elimination or reduction of parasites to effect a clinical cure. Differential expression of these determinants alone by parasites may alter their interactions with the hosts. Virulent phenotype is consequently presented as a spectrum of manifestations from asymptomatic infection to fatality. A secondary level of regulation lies in host genetic and environmental factors. The model suggests that different parasite determinants may be targeted by different strategies to achieve more effective control of leishmaniasis and other similar diseases.

### Introduction

Some *Leishmania* species are inherently endowed as pathogens, as they cause diseases collectively known as leishmaniasis. The degree of their pathogenicity, traditionally defined as "virulence", is manifested as a spectrum of clinical symptoms in human diseases [1]. Those causing a self-healing cutaneous leishmaniasis are considered as less virulent than those causing the potentially fatal kala-azar or visceral leishmaniasis. Disease entities with graded

clinical severity exist between these two extremes. Although *Leishmania* virulence may be modulated by environmental and genetic factors of their mammalian hosts [2], and sand fly vectors [3], molecular determinants of *Leishmania* spp. are the key elements. This is considered to be the case, since there is no leishmaniasis without infection by intact living *Leishmania*. That is, leishmaniasis does not occur, or at least has not been successfully duplicated experimentally, by injection or manipulation of an-

imals with anything other than viable *Leishmania* parasites. There is no evidence in the literature that *Leishmania* spp. produce "toxins" in the conventional sense to directly cause the clinical symptoms of leishmaniasis. How *Leishmania* cause leishmaniasis is thus a complicated issue, involving apparently multiple factors of *Leishmania* origin.

Work undertaken in the past two decades to elucidate host-parasite cellular interactions has made this point apparent. It is clear that *Leishmania* possess infection-related molecules (=invasive/evasive determinants) [1], which allow them to establish successful intracellular parasitism in phagolysosomes or parasitophorous vacuoles of macrophages [4]. In human leishmaniasis, these mononuclear phagocytes are invariably seen as the only parasitized cells. They are thus undoubtedly the principal host cells of *Leishmania*, although experimental evidence exists for leishmanial infection of other cell types, e.g. dendritic cells [5] and fibroblasts [6,7]. The association of *Leishmania* with macrophages at the cellular level is characterized as akin to "symbiosis" [8]. This notion was proposed from observations of host-parasite cellular interactions in the *L. amazonensis*-J774 macrophage *in vitro* system [9]. In that case, the infection produces no acute cytopathology or rapid cytolysis of the host cells. It is essentially a self-renewable or self-sustainable host-parasite *in vitro* system. Since human disease does occur with infection of macrophages *in vivo*, it is likely that the pathology and clinical symptoms may originate from interactions of these infected macrophages with other elements in the host. We propose here that some parasite-specific antigens, derived from the infected cells, interact with the host immune system in a negative way, directly responsible for the immunopathology manifested as the clinical symptoms seen in leishmaniasis. Consistent with this notion are findings that kala-azar patients produce large amounts of *Leishmania*-specific, but non-protective antibodies against certain intracellular antigens of these organisms [10].

A hypothetical model is thus proposed accordingly, depicting that *Leishmania* virulence results from interactions of different *Leishmania* determinants with separate compartments of host immune system, namely those for infection and those involved in immunopathology. If the hypothetical model proves correct, the two groups of determinants may be targeted differently by molecular genetic approaches relevant to the control of leishmaniasis.

***Invasive/evasive determinants of Leishmania are crucial for infection, but produce no pathology in the host***

These determinants include most, if not all *Leishmania* molecules that have been studied as "virulence factors" in the literature (see Fig. 1). All these molecules appear to play certain roles in *Leishmania* infection of macrophages

- Glycosylphosphatidylinositol (GPI)
- Glycosylphospholipid (GIPL)
- Lipophosphoglycans (LPG)
- Phosphoglycans (PG)
- Proteophosphoglycans (PPG)
- Leishmanolysin (gp63)
- Cysteine proteases (CPs)
- Others

**Figure 1**

Some invasive/evasive determinants of *Leishmania* proposed to play important roles in their infection of mammalian hosts.

[1]. They are referred to here as invasive/evasive determinants because they help *Leishmania* successfully establish intracellular parasitism in the following sequential events: (A) evasion of humoral lytic factors; (B) attachment of parasites to macrophages followed by their intracellular entry into these phagocytes; (C) the intracellular survival of the endocytized parasites; (D) promastigote-to-amastigote differentiation; and (E) replication of the amastigotes. The categorization of the host-parasite cellular interactions into sequential events pertains to the primary infection of macrophages in the mammalian hosts by promastigotes. Events (A) – (C) and (E) are relevant as well to the secondary infection of macrophages by amastigotes from already infected cells. The spreading of amastigotes to infect additional cells must be considered as crucial for the development of leishmaniasis. However, it may be mechanistically a rather simple event in considering normal functions of macrophages. One of their functions is to scavenge damaged or dying cells and their cellular debris, which may include degenerating cells (due to heavy parasitization), parasitophorous vacuoles and even released amastigotes with adherent host molecules in leishmaniasis.

Much attention has been thus devoted to the infection of macrophages by promastigotes, although the manner, by which their molecules (listed in Fig. 1) actually function in infection remains to be elucidated. Data obtained from different host-parasite systems are also not always consistent even for the molecules more extensively studied, like gp63 and LPG. Gp63 is an ecto-metalloprotease that is especially abundant in the surface of promastigotes and also released by this stage of *Leishmania* [11]. Gp63 is known to help promastigotes in event (A) by rendering them resistant to complement-mediated cytolysis [12]. It also appears to act, (perhaps, together with LPG) in event (B), namely infection of macrophages by promastigotes via receptor-mediated endocytosis [13–16]. Both may be im-

### Unique epitopes in conserved protein complex:

- Cytoskeleton, e. g. kinesin, tubulins
- Chaperones, e. g. HSP 60, 70, 83 & STI 1
- Ribosomes, e. g. eIF, PO, P2a, b
- Nucleosomes, e. g. H2A/B, H3, H4
- Glycosomes, e. g. TPI
- Spliceosomes ?
- Proteosomes ?

Requena, Alonso, Soto (2000) *Parasitol. Today* 16, 246-50

### Figure 2

Some *Leishmania* pathoantigenic determinants proposed to cause immunopathology manifested as the clinical symptoms in leishmaniasis. The molecules listed have been found to contain immunogenic B-cell epitopes.

portant in event (C) for their intraphagolysosomal survival [16–18]. Some of the other molecules listed in Fig. 1 may be involved directly or indirectly in these and/or the remaining events. Parasite molecules involved in events (D) and (E) for differentiation and replication of intracellular *Leishmania* may have additional functions beyond infection, especially in the latter case. Regardless of the functional and definitional ambiguity associated with these determinants, there is no evidence that they directly cause the clinical symptoms seen in leishmaniasis. For example, repeated injections of susceptible animals with gp63 or LPG do not reproduce the typical symptoms of leishmaniasis, e.g. various types of cutaneous lesions or hepatosplenomegaly and other clinical signs related to kala-azar.

### ***Leishmania* pathoantigenic determinants elicit host immunopathology as the principal cause of clinical symptoms**

Fig. 2 lists a number of *Leishmania* antigens found to elicit antibodies often at high titers in kala-azar patients [10]. The data presented were summarized from articles published by others and some are proposed hypothetically. These *Leishmania* antigens are identified by Western blot analysis and/or by immunoscreening of *Leishmania* expression libraries with patients' sera.


Notably, Fig. 2 does not include the invasive/evasive determinants discussed in the foregoing paragraph. This is not to say that patients of leishmaniasis do not produce any antibodies against these determinants. There have been a number of publications, which demonstrated the presence of, for example, anti-LPG and anti-gp63 antibodies in these patients. However, the titers against these invasive/evasive determinants are insignificant in comparison to those listed in Fig. 2. Perhaps, this is not

unexpected for a successful parasite, like *Leishmania*. Since the invasive/evasive determinants often exist on the cell surface and/or are secreted, they bear the brunt of exposure to and confrontation with the host immune system. Evolutionary pressure may well select these invasive/evasive determinants for low antigenicity, thereby escaping from neutralization by specific antibodies and/or other lytic factors to ensure successful parasitism.

Another striking feature of those listed in Fig. 2 is that they are all conserved structural or soluble cytoplasmic proteins, which are often complexed with other molecules to form subcellular particles. Although some of them, e.g. histones and heat shock proteins, are seemingly shared with those found in autoimmune diseases, they are not cross-reactive. Epitope-mapping reveals unique *Leishmania* sequences, which are recognized only by sera from patients with kala-azar [10]. One example worthy of mention is the unique 117 bp repeats in the *Leishmania* kinesin-like gene [19]. It is expressed by the amastigotes of visceralizing *Leishmania*, but not by cutaneous species. Sera from human kala-azar patients contain antibodies specific to the 39 amino acid peptides encoded by the 117 bp repeats (recombinant products =rK39). Anti-rK39 antibodies reach exceedingly high titers as much as  $10^{-6}$  in Indian kala-azar patients [20]. Although this antigen has been used successfully for serodiagnosis of active kala-azar cases, it is difficult to assign any protective function for the specific antibodies at such high titers produced against this and other similar antigens. The antigens of concern are in the cytoplasm of intracellular amastigotes and thus beyond the reach of these antibodies. Their potential contributions to immunopathology are apparent, e. g. albumin-IgG ratio reversal in the plasma and hyperplasia of plasma cells in the lymphoid organs in kala-azar. Similarly, some *Leishmania*-specific T-cell epitopes may also exist and cause additional immunopathology, although these epitopes have not been extensively studied in human leishmaniasis. Recent work in the direction of elucidating protective immunity has identified T-cell epitopes, which exist also in *Leishmania* cytoplasmic molecules [21].

### **A hypothetical model for *Leishmania* virulence involving sequential actions of invasive/evasive- and pathoantigenic determinants**

Fig. 3 depicts schematically *Leishmania* invasive/evasive- and pathoantigenic determinants as different groups of parasite virulence-related molecules. Presumably, they interact sequentially with different compartments of the host immune system to cause leishmaniasis. The invasive/evasive determinants of *Leishmania* help them overcome the host immune and non-immune barriers to establish intracellular infection of macrophages. This infection by itself does not cause the disease, but it is a prerequisite for



**Figure 3**

A hypothetical model to explain virulent phenotype in leishmaniasis. The three groups of determinants are thought to interact with host immune system independently, but may progress sequentially to produce the spectrum of subclinical and clinical manifestations as the basis of virulent phenotypes seen.


this state. Infection must be maintained in order for the transition from asymptomatic phase to symptomatic phase, especially when host immunity becomes down-regulated. The latter event alone produces no leishmaniasis without persistence of the infection. The invasive/evasive determinants are thus virulence factors in that sense, even though they contribute only indirectly to the virulent phenotype. During the subsequent chronic course of infection, it appears that some intracellular amastigotes are killed or lysed inadvertently due, perhaps, to the incomplete protection by their invasive/evasive determinants. As a result of this, some cytoplasmic molecules of amastigotes are exposed to the host immune system. The resulting immune response to these unique epitopes does not contribute to the anti-*Leishmania* immunity, but to the clinical symptoms observed in leishmaniasis. Thus, *Leishmania* determinants of infection and immunopathology are considered here as different, but sequentially necessary components for the expression of virulence.

#### Regulation of *Leishmania* virulence

According to the hypothetical model, it is possible to envision the regulation of *Leishmania* virulence via differential expression or qualitative differences of the invasive/evasive and pathoantigenic determinants. Virulence is manifested in a clinical setting as a spectrum of human diseases with different severity, ranging from asymptomatic infection to the appearance of self-healing nodules to necrotic, diffuse mucocutaneous lesions to fatal viscer-

alizing disease. Up- or down-regulation of either group of individual determinants quantitatively or qualitatively alone can conceivably result in the spectrum of the clinical outcomes seen. The extreme scenarios of asymptomatic infection and fatal outcome thus may be due to a pattern of varying expression of these determinants. In this view, *Leishmania* determinants are considered as the driving force of virulent phenotype. Host and vector determinants are undoubtedly involved, but they play a secondary or passive role in natural conditions.

Fig. 4 considers *Leishmania* virulence at the gene level based on hypothetical grounds and on some gene knock-out experimental data in the literature. There appear to be three functional groups of genes involved: (A) Positive contributors for the multiple determinants already discussed (Fig. 4., Blue, Green and Yellow squares with "+"); (B) negative contributors (pink square with "-") coding for products, which reduce virulence; and (C) facultative contributors (Red square blank), which normally do not participate in virulence, but do so in the absence of a positive contributor. Normally, the virulent phenotype seen in a given condition represents a balanced presence of positive and negative genes with no involvement of the facultative ones (Fig. 4, 1st row, double-headed horizontal arrow). When one of the positive genes is silenced or lost, virulence may decrease, as expected (Fig. 4, 2nd row, downward arrow). Alternatively, it may remain unchanged when the gene of concern is functionally "backed

**Figure 4**

Regulation of *Leishmania* virulence at genetic levels. Blue, Green and Yellow squares with "+", Positive contributors for the multiple determinants discussed; pink square with "-", negative contributors coding for products, which reduce virulence; Red square blank, Facultative contributors, which do not contribute to virulence under the normal conditions.

up" or replaced with another positive contributor via up-regulation of its expression (Fig. 4, 3rd Row, duplication of the green squares with "+") or with that of a facultative gene (Fig. 4, 4th row, red square with "+"). This scenario may explain the experimental findings that knockouts of "virulence genes" do not always result in changes in the phenotype expected. Silencing or loss of the negative gene is accompanied by an increase in virulence (Fig. 4, 6th Row, upward arrow). There is at least one example in the literature for the presence of negative genes [22].

The hypothesis proposed is speculative, especially for the presence of the "back-up" genes. Although they have not been demonstrated experimentally in *Leishmania*, functionally overlapping genes with very different sequences are expected to exist, in keeping with the proposed contribution of such genes to genetic flexibility in biological systems [23]. If such a strategy should exist in *Leishmania* and contribute to the regulation of their virulence, the evolutionary pressure of maintaining successful parasitism might favor this mechanism for the invasive/evasive determinants, but not for the pathoantigenic determinants.

#### **Can we temper with *Leishmania* virulence genes to deal with leishmaniasis?**

More genetic and functional data for the various determinants discussed are needed to consider this question more thoroughly. On hypothetical grounds, it is possible to consider that: (A) the invasive/evasive determinants may be targeted for developing specific inhibitors to prevent infection; and (B) the pathoantigenic determinants may be suitable targets for considering "molecular attenuation" of virulence by gene deletions or modifications, thereby producing infective, but non-pathogenic mutants for vaccination. The schemes related to the second proposal may be more interesting for further discussion.

It is feasible to begin the discussion with the self-curing simple cutaneous leishmaniasis. In this case, "host protective determinants" of *Leishmania* origin are depicted to emerge with the progression of the infection from "disease" to spontaneous "cure" (see Fig. 3). These hypothetical determinants may be the "natural vaccines", which interact with the host immune system in a positive way to cure the disease. Although they have not been identified and isolated, there are ongoing research efforts toward this end [21]. On the other hand, "Leishmanization" has been practiced for centuries by inoculating or immunizing individuals with live *Leishmania*. Although this process

leads to development of cutaneous lesions, it provides life-long protection to re-infection by the same species after cure. It is theoretically possible to improve "Leishmanization" by several potential schemes. One is to genetically engineer parasites with "suicidal cassettes" [24] for self-destruction as a strategy for vaccination, as has been already carried out in experimental animals [25]. It would be of further interest to improve this by "immunizing" susceptible hosts with such transgenic *Leishmania*, which are responsive to external signals for their destruction [26,27] at different times after inoculation. Perhaps, effective immunity could be activated by such manipulation before the manifestation of extensive clinical pathology. "Leishmanization" thus may become more effective or rendered more innocuous. Another possibility is to delete or modify the gene(s) encoding pathoantigenic determinants. Although this is a more desirable approach, it will require a substantial investment to identify and select suitable targets. This is the case, since these determinants appear to be encoded apparently by conserved and thus functionally important genes. Candidates may include antigens empirically identified for vaccination against kala-azar. There may be sufficient incentives to produce such attenuated mutants in considering the potential benefits that they may be used as vehicle for delivery of antigens as vaccines for other diseases. This may be considered in view of the "homing" of *Leishmania* to macrophages (and possibly dendritic cells). These "vaccines" could be transgenetically expressed by *Leishmania* for targeted delivery and accumulation in these cells. Antigen processing and presentation may be rendered more effective to achieve desirable immune response.

## Discussion

*Leishmania* virulence has been discussed often in the context of infection-related molecules or invasive/evasive determinants, independent of the pathoantigenic determinants. A hypothetical model is presented to depict infection, virulence and cure as sequential, but independent events. The actions of both groups of determinants in tandem are proposed here to cause leishmaniasis. This hypothetical model is probably applicable to other chronic infections caused by nontoxigenic pathogens. If so, the proposed differential targeting strategies could have broader applications. The actual translation of these ideas for fighting leishmaniasis and other infectious diseases into practical use requires additional studies. However preliminary the schemes may seem, they deserve consideration and discussion for the sake of millions who suffer from these diseases in the developing world. It is desirable to develop field deployable products for preventing these diseases, but this has been hampered by the lack of investment by the pharmaceutical industry. Hopefully, this obstacle will be rendered easier to overcome under the

coattails of our renewed interests in vaccines in the war against bioterrorism.

## Acknowledgements

The authors are supported by the NIH (AI-20486 to KPC) and the American Heart Association (Physician-Scientist Postdoctoral Fellowship to BSM).

## References

1. Chang KP, Chaudhuri G, Fong D: **Molecular determinants of *Leishmania* virulence.** *Annu Rev Microbiol* 1990, **44**:499-529
2. Blackwell JM: **Genetic susceptibility to leishmanial infections: studies in mice and man.** *Parasitology* 1996, **112**:S67-74
3. Titus RG, Ribeiro JM: **Salivary gland lysates from the sand fly *Lutzomyia longipalpis* enhance *Leishmania* infectivity.** *Science* 1988, **239**:1306-1308
4. Chang KP, Dwyer DM: **Multiplication of a human parasite (*Leishmania donovani*) in phagolysosomes of hamster macrophages in vitro.** *Science* 1976, **193**:678-680
5. Qi H, Popov V, Soong L: ***Leishmania amazonensis*-dendritic cell interactions in vitro and the priming of parasite-specific CD4(+) T cells in vivo.** *J Immunol* 2001, **167**:4534-4542
6. Chang KP: ***Leishmania* infection of human skin fibroblasts in vitro: absence of phagolysosomal fusion after induced phagocytosis of promastigotes, and their intracellular transformation.** *Am J Trop Med Hyg* 1978, **27**:1084-1096
7. Bogdan C, Donhauser N, Doring R, Rollinghoff M, Diefenbach A, Rittig GM: **Fibroblasts as host cells in latent leishmaniasis.** *J Exp Med* 2000, **191**:2121-2130
8. Chang KP: **Cellular and molecular mechanisms of intracellular symbiosis in leishmaniasis.** *Intl Rev of Cytol - Suppl* 1983, **14**:267-305
9. Chang KP: **Human cutaneous leishmania in a mouse macrophage line: propagation and isolation of intracellular parasites.** *Science* 1980, **209**:1240-1242
10. Requena JM, Alonso C, Soto M: **Evolutionarily conserved proteins as prominent immunogens during *Leishmania* infections.** *Parasitol Today* 2000, **16**:246-250
11. McGwire BS, O'Connell WA, Chang KP, Engman DM: **Extracellular release of the glycosylphosphatidylinositol (GPI)-linked *Leishmania* surface metalloprotease, gp63, is independent of GPI phospholipolysis.** *J Biol Chem* 2002, **277**:8802-8809
12. Brittingham A, Morrison CJ, McMaster WR, McGwire BS, Chang KP, Mosser DM: **Role of the *Leishmania* surface protease gp63 in complement fixation, cell adhesion, and resistance to complement-mediated lysis.** *J Immunol* 1995, **155**:3102-3111
13. Chang CS, Chang KP: **Monoclonal antibody affinity purification of a *Leishmania* membrane glycoprotein and its inhibition of leishmania-macrophage binding.** *Proc Natl Acad Sci USA* 1986, **83**:100-104
14. Russell DG, Wilhelm H: **The involvement of the major surface glycoprotein (gp63) of *Leishmania* promastigotes in attachment to macrophages.** *J Immunol* 1986, **136**:2613-2620
15. Liu X, Chang KP: **Extrachromosomal genetic complementation of surface metalloproteinase (gp63)-deficient *Leishmania* increases their binding to macrophages.** *Proc Natl Acad Sci USA* 1992, **89**:4991-4995
16. McGwire B, Chang KP: **Genetic rescue of surface metalloproteinase (gp63)-deficiency in *Leishmania amazonensis* variants increases their infection of macrophages at the early phase.** *Mol Biochem Parasitol* 1994, **66**:345-347
17. Beverley SM, Turco SJ: **Lipophosphoglycan (LPG) and the identification of virulence genes in the protozoan parasite *Leishmania*.** *Trends Microbiol* 1998, **6**:35-40
18. Chaudhuri G, Chaudhuri M, Pan A, Chang KP: **Surface acid proteinase (gp63) of *Leishmania mexicana*. A metalloenzyme capable of protecting liposome-encapsulated proteins from phagolysosomal degradation by macrophages.** *J Biol Chem* 1989, **264**:7483-7489
19. Burns JM Jr, Shreffler WG, Benson DR, Ghalib HW, Badaro R, Reed SG: **Molecular characterization of a kinesin-related antigen of *Leishmania chagasi* that detects specific antibody in African and American visceral leishmaniasis.** *Proc Natl Acad Sci U S A* 1993, **90**:775-779

20. Singh S, Gilman-Sachs A, Chang KP, Reed SG: **Diagnostic and prognostic value of K39 recombinant antigen in Indian leishmaniasis.** *J Parasitol* 1995, **81**:1000-1003
21. Probst P, Stromberg E, Ghalib HW, Mozel M, Badaro R, Reed SG, Webb JR: **Identification and characterization of T cell-stimulating antigens from *Leishmania* by CD4 T cell expression cloning.** *J Immunol* 2001, **166**:498-505
22. Cunningham ML, Titus RG, Turco SJ, Beverley SM: **Regulation of differentiation to the infective stage of the protozoan parasite *Leishmania major* by tetrahydrobiopterin.** *Science* 2001, **292**:285-287
23. Krakauer DC, Plotkin JB: **Redundancy, antiredundancy, and the robustness of genomes.** *Proc Natl Acad Sci U S A* 2002, **99**:1405-1409
24. LeBowitz JH, Cruz A, Beverley SM: **Thymidine kinase as a negative selectable marker in *Leishmania major*.** *Mol Biochem Parasitol* 1992, **51**:321-325
25. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM: **Development of a safe live *Leishmania* vaccine line by gene replacement.** *Proc Natl Acad Sci U S A* 1995, **92**:10267-10271
26. Yan S, Myler PJ, Stuart K: **Tetracycline regulated gene expression in *Leishmania donovani*.** *Mol Biochem Parasitol*. 2001, **112**:61-9
27. Sah JF, Ito H, Kolli BK, Peterson DA, Sassa S, Chang KP: **Genetic rescue of *Leishmania* deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyrin and photodynamic therapy.** *J Biol Chem* 2002, **277**:14902-14909

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMedcentral will be the most significant development for disseminating the results of biomedical research in our lifetime."

Paul Nurse, Director-General, Imperial Cancer Research Fund

Publish with **BMC** and your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours - you keep the copyright

Submit your manuscript here:

<http://www.biomedcentral.com/manuscript/>



**BioMedcentral.com**

[editorial@biomedcentral.com](mailto:editorial@biomedcentral.com)